VisionCare Specialist Eye Hospital Business Plan › Section 3 › Industry & Market Analysis

This section establishes the size, structure and growth dynamics of
the South African eye care market, the epidemiological burden of eye
disease that drives demand, the funding environment, and the structural
supply constraints that create the opportunity for a focused specialist
hospital.

3.1 The Burden of Eye Disease in South Africa

Eye disease represents one of the most significant and
least-addressed components of the South African disease burden. A
systematic review and meta-analysis of the period 2010–2020 estimated
the prevalence of blindness at approximately 2% and moderate-to-severe
visual impairment (MSVI) at approximately 12% of the affected population
studied. Crucially, the dominant causes are treatable: uncorrected
refractive error, cataract, glaucoma and diabetic retinopathy together
account for the overwhelming majority of vision loss.

Figure 3.1

National guidelines have historically estimated blindness prevalence
at around 0.75%, while more recent population work places it closer to
0.90%. Cataract is estimated to be responsible for roughly half of all
blindness in South Africa — affecting on the order of 170,000 people —
and is almost entirely curable through a routine, high-volume surgical
procedure. Community surveys in provinces such as Limpopo have recorded
cataract prevalence as high as 44% among older adults, with low
awareness and limited access to surgery cited as the principal
barriers.

3.2 Market Size & Growth

The South African ophthalmic devices market — a useful proxy for the
scale and momentum of clinical ophthalmic activity — was estimated at
approximately USD 237.7 million in 2024 and USD 248.6 million in 2025,
and is forecast to grow at a compound annual growth rate (CAGR) of
approximately 4.41% to reach roughly USD 308.5 million by 2030. This
steady, demographically-underpinned growth reflects rising procedure
volumes, technology adoption (premium intraocular lenses,
femtosecond-assisted surgery, advanced imaging) and the expansion of
intravitreal therapy.

Figure 3.2

The broader private healthcare market in which VisionCare will
operate is large, well-developed and concentrated. South Africa runs a
two-tier system: a public sector serving the majority of the population,
and a sophisticated private sector funded primarily through medical
schemes. Approximately 9.7 million people — around 15.8% of the
population — are covered by medical schemes, and this funded segment
supports private hospital infrastructure broadly regarded as among the
most advanced in the developing world.

3.3 The Funding Environment

Medical schemes are the primary payer for private ophthalmic care.
While scheme membership growth has been slow and the membership base is
ageing — placing upward pressure on contributions — the absolute funded
population remains substantial and the demand for medically-necessary
eye surgery is highly inelastic. Cataract surgery, glaucoma management,
vitreoretinal intervention and anti-VEGF therapy are standard scheme
benefits, typically funded from risk pools rather than savings accounts,
which insulates volumes from short-term economic pressure on
members.

The National Health Insurance (NHI) Act was signed into law in 2024.
Although its implementation timeline, funding mechanism and the future
role of medical schemes remain subject to consultation and legal
challenge, the directional intent is to expand access to care. A
well-run, accredited, cost-efficient specialist eye hospital is
well-positioned under either the status quo or a future NHI-contracting
environment, given that high-volume cataract and screening services are
precisely the kind of cost-effective interventions that any
universal-coverage system must scale.

Table 3.1 — Structural demand drivers and strategic
implications

3.4 Addressable Market & Demand Quantification

VisionCare’s addressable market can be sized from the bottom up. The
medical-scheme-covered population is approximately 9.7 million people.
International epidemiology indicates that, in any given year, a
meaningful proportion of an insured, ageing population requires
ophthalmic intervention: comprehensive examination, cataract assessment
and surgery, glaucoma monitoring, retinal screening, or refractive
correction. Even capturing a small single-digit share of the procedures
generated within the catchment area of a single metropolitan facility is
sufficient to fill the planned capacity several times over.

To illustrate the depth of demand, consider cataract alone. With
cataract responsible for roughly half of blindness in South Africa and
affecting an estimated 170,000 people nationally — before accounting for
the far larger pool of visually-significant but not-yet-blinding
cataract — the surgical backlog is profound. A single high-throughput
facility performing 2,000–3,000 cataract procedures annually addresses
only a fraction of the unmet need within its region. The same logic
applies to the recurring anti-VEGF injection market, which expands
mechanically with diabetes prevalence.

Table 3.2 — Addressable market and demand quantification

Beyond the funded private market, the economic cost of avoidable
blindness and vision impairment — measured in lost productivity and
care-giver burden — is substantial and provides the policy rationale for
public-private partnership and outreach. This dual market (funded
private demand plus a policy-supported public/outreach component) gives
VisionCare an unusually robust demand foundation for a private
healthcare asset.

3.5 Supply-Side Constraints

The defining feature of the African eye care market is a chronic
shortage of ophthalmic specialists. Many sub-Saharan countries report
fewer than one ophthalmologist per million population, and even in
better-resourced South Africa the specialist workforce is heavily
concentrated in major metropolitan centres and the private sector. This
maldistribution lengthens public waiting lists, suppresses surgical
throughput and creates a clear opening for a privately-funded,
high-efficiency hospital that can recruit and retain sub-specialists by
offering modern facilities, predictable theatre time and an attractive
case mix.

Africa carries close to a fifth of the global burden of vision loss
while representing about 12% of the world’s population — a disproportion
driven precisely by inadequate facilities and workforce shortages. For
VisionCare, this asymmetry is the core of the investment thesis: demand
is structural and growing, while supply is constrained and slow to
expand.

3.6 Industry Trends & Innovation

Several structural trends are reshaping ophthalmic care and reinforce
the case for a modern, technology-led specialist hospital. Each
represents both a clinical opportunity and a source of revenue and
differentiation for VisionCare.

• Premium intraocular lenses: growing patient
  demand for multifocal, extended-depth-of-focus and toric lenses lifts
  the average revenue per cataract case and supports a cash-pay upgrade
  pathway alongside scheme-funded standard lenses.
• Femtosecond-assisted & minimally-invasive
  surgery: laser-assisted cataract surgery and MIGS improve
  precision and recovery, attract patients and clinicians, and command
  premium positioning.
• Expansion of intravitreal therapy: the anti-VEGF
  treatment burden grows mechanically with diabetes prevalence and an
  ageing population, creating a high-frequency, annuity-like revenue
  stream.
• Tele-ophthalmology & AI screening:
  AI-assisted retinal screening and remote triage extend the referral
  funnel into primary care and outreach settings at low marginal cost, and
  align with cost-effective universal-coverage objectives.
• Outcomes transparency & value-based care:
  payers increasingly reward demonstrable quality; a focused hospital with
  registry-grade outcomes data is well-placed in future value-based
  contracting.

VisionCare’s capital plan deliberately funds the platforms (laser,
advanced imaging, premium-lens capability and a modern EMR) needed to
capture these trends from day one, rather than retrofitting later at
higher cost and disruption.

3.7 PESTEL Snapshot

Table 3.4 — PESTEL analysis of the operating environment

Confidential — this business plan is provided to prospective investors and lenders for evaluation purposes only and may not be reproduced or distributed without the written consent of VisionCare Specialist Eye Hospital (Pty) Ltd.